Item 7.01 Regulation FD Disclosure.

From time to time, Syros Pharmaceuticals, Inc. (the "Company") intends to conduct meetings with third parties in which its current corporate slide presentation is presented. A copy of this slide presentation, dated January 2023, is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information responsive to Item 7.01 of this Form 8-K and Exhibit 99.1 hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 8.01 Other Events.

On January 9, 2023, we issued a press release announcing our 2023 business objectives. The full text of this press release is filed as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference. The information contained on the websites referenced in the press release is not incorporated herein.

--------------------------------------------------------------------------------

Item 9.01 Financial Statements and Exhibits.





Exhibit No.                                  Description

99.1                Slide Presentation, dated January 2023

99.2                Press Release, dated January 9, 2023

104               Cover Page Interactive Data File (embedded within the Inline XBRL
                  document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses